
Claims:

1. A (thio)-carbamoyl-cyclohexane derivative of formula(I)



(I)

wherein

R_1 and R_2 are each, independently hydrogen, alkyl, alkenyl, aryl, cycloalkyl, aroyl, or R_1 and R_2 form a heterocyclic ring with the adjacent nitrogen atom;

X is O or S;

n is 1 or 2;

and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof for use in the treatment of acute mania.

2. The use according to claim 1, wherein the compound of formula (I) is trans-4-{2- [4-(2,3-dichlorophenyl)-piperazin-l-yl]-ethyl}-N,N-dimethylcarbamoyl- cyclohexylamine and/or salts and/or hydrates and/or solvates and/or polymorphs thereof.

3. The use according to claim 1, wherein the compound of formula (I) is trans-4-{2- [4-(2,3-dichlorophenyl)-piperazin-l-yl]-ethyl}-N,N-dimethylcarbamoyl- cyclohexylamine hydrochloride and/or hydrates and/or solvates and/or polymorphs thereof.

4. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 0.1 to 12 mg.

5. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 0.5 mg.6. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 1.0 mg.

7. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 1.5 mg.

8. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 3 mg.

9. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 4.5 mg.

10. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 6 mg.

11. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 9 mg.

12. The use according to claim 4 wherein the therapeutically effective amount of a compound of formula (I) is about 12 mg.

13. The use according to any one of claims 4-12, wherein a compound of formula (I) is administered in one, two, three or four divided daily doses.

14. The use according to any one of claims 4-13, wherein acute mania is associated with bipolar disorder.


15. The use according to claim 14, wherein the bipolar disorder is bipolar I disorder.

16. The use according to claim 14, wherein the bipolar disorder is bipolar II disorder.

17. The use according to claim 14, wherein the bipolar disorder is cyclothymic disorder.

18. The use according to any one of claims 4-13, wherein acute mania is associated with acute manic and mixed episodes.

19. The use of (thio)-carbamoyl-cyclohexane derivatives of formula (I)



(I)

wherein

R_1 and R_2 are each, independently hydrogen, alkyl, alkenyl, aryl, cycloalkyl, aroyl, or Ri and R_2 form a heterocyclic ring with the adjacent nitrogen atom;

X is O or S;

n is 1 or 2;

and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof in a therapeutical effective amount in the manufacture of a medicament for the treatment of acute mania.

20. The use according to claim 19 characterized by that the compound of formula (I) is trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or salts and/or hydrates and/or solvates and/or polymorphs thereof.

21. The use according to claim 19 characterized by that the compound of formula (I) is trans-4- {2-[4-(2,3-dichlorophenyl)-piperazin- 1 -yl] -ethyl } -N,N-dimethylcarbamoyl-cyclohexylamine hydrochloride and/or hydrates and/or solvates and/or polymorphs thereof.

22. The use according to any one of the claims 19-21 characterized by that the therapeutically effective amount of a compound of formula (I) is about 0.1 to 12 mg.

23. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 0.5 mg.

24. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 1.0 mg.

25. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 1.5 mg.

26. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 3.0 mg.

27. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 4.5 mg.

28. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 6 mg.

29. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 9 mg.

30. The use according to claim 22 characterized by that the therapeutically effective amount of a compound of formula (I) is about 12 mg.

31. The use according to any one of claims 22-30 characterized by that the therapeutically effective amount of a compound of formula (I) is divided into one, two, three or four daily doses.

32. The use according to any one of claims 22-31 characterized by that acute mania is associated with bipolar disorder.

33. The use according to claim 32 characterized by that the bipolar disorder is bipolar I disorder.

34. The use according to claim 32 characterized by that the bipolar disorder is bipolar II disorder.

35. The use according to claim 32 characterized by that the bipolar disorder is cyclothymic disorder.

36. The use according to any one of claims 22-31 characterized by that the acute mania is associated with acute manic and mixed episodes.

CLAIMS

1. A carbamoyl-cyclohexane derivative selected from trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or salts and/or hydrates and/or solvates and/or polymorphs thereof, in a therapeutically effective amount for use in a method of treating acute mania by oral administration thereof, wherein the therapeutically effective amount is 3 to 12 mg/day.

2. Carbamoyl-cyclohexane derivative for use according to claim 1, wherein the carbamoyl-cyclohexane derivative is trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine hydrochloride and/or hydrates and/or solvates and/or polymorphs thereof.

3. Carbamoyl-cyclohexane derivative for use according to claim 1 or 2 **characterized by** that the therapeutically effective amount is 3.0 mg/day.

4. Carbamoyl-cyclohexane derivative for use according to claim 1 or 2 **characterized by** that the therapeutically effective amount of is 4.5 mg/day.

5. Carbamoyl-cyclohexane derivative for use according to claim 1 or 2 **characterized by** that the therapeutically effective amount is 6 mg/day.

6. Carbamoyl-cyclohexane derivative for use according to claim 1 or 2 **characterized by** that the therapeutically effective amount of 9 mg/day.

7. Carbamoyl-cyclohexane derivative for use according to claim 1 or 2 **characterized by** that the therapeutically effective amount is 12 mg/day.

8. Carbamoyl-cyclohexane derivative for use according to any one of claims 1-7 **characterized by** that the therapeutically effective amount is divided into one, two, three or four daily doses.

9. Carbamoyl-cyclohexane derivative for use according to any one of claims 1-8 **characterized by** that the acute mania is associated with bipolar disorder.

10. Carbamoyl-cyclohexane derivative for use according to claim 9 **characterized by** that the bipolar disorder is bipolar I disorder.

11. Carbamoyl-cyclohexane derivative for use according to claim 9 **characterized by** that the bipolar disorder is bipolar II disorder.

12. Carbamoyl-cyclohexane derivative for use according to claim 9 **characterized by** that the bipolar disorder is cyclothymic disorder.

13. Carbamoyl-cyclohexane derivative for use according to any one of claims 1-7 **characterized by** that the acute mania is associated with acute manic and mixed episodes.